BIO vs INVA · rev $651.0M vs P/E 3.6, rev $217.6M
BIO (BIO) versus Innoviva Inc (INVA) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Innoviva Inc (INVA) is a biotechnology company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported INVA revenue for 2026-06-30 was $217.6M. Net income was $103.2M. INVA currently screens at market cap $1.66B and trailing P/E 3.6.
BIO currently screens at market cap $0. INVA currently screens at market cap $1.66B and trailing P/E 3.6.
Not investment advice. Open the BIO and INVA stock pages for the full models.
Not investment advice.